Tempus AI, Inc. , a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025.

Although common, the cause of these hernias is unknown, and the only treatment ... Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer Feb. 5, 2025 — Researchers report ...

James William Rogers (NYSE:ROG), the Chief Financial Officer of Tempus AI , Inc. (NASDAQ:TEM), recently sold 8,712 shares of the company’s Class A common stock. The shares were sold at a weighted ...

Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

We came across a bullish thesis on Tempus AI, Inc. (TEM) on Substack by Market Moves by GBC. In this article, we will ...

Tempus AI's innovative products are transforming the healthcare industry, with a focus on oncology and large market opportunities. See why TEM stock is a Buy.